Safety and immune response study of VAX-A1 vaccine in healthy young adults
Part of Infections clinical trials.
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old
- You are in overall good health with no serious medical conditions
- You have not had recent Group A Streptococcus infection or related complications
- You do not have an autoimmune disease, HIV, hepatitis B or C, or a bleeding disorder
- You can attend follow-up visits for 6 months after your second vaccine dose
- You can use a smartphone, tablet, or computer to complete a daily diary during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine designed to protect against Group A Strep bacteria. It will check how safe the vaccine is and how well it boosts your immune system. Healthy young adults between 18 and 25 years old may be eligible.
This trial tests a vaccine called StreptInCor to see if it's safe and helps the body build immunity against strep bacteria. It may help prevent serious complications like rheumatic fever and heart damage.
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
This study tests an experimental COVID-19 vaccine to see if it is safe and how well it works against current variants. It is for healthy adults who have had a previous COVID-19 vaccine or infection.
This trial tests a new vaccine to prevent Group B Strep (GBS) infection, given alone or with the Tdap vaccine. It aims to see if the combination is safe and works well in healthy women aged 18 to 49.
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
Hear when a new Group A Streptococcal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.